Annovis to Host Corporate Update Webinar on January 28, 2026
Rhea-AI Summary
Annovis (NYSE: ANVS) will host a corporate update webinar on January 28, 2026 at 4:30 p.m. ET featuring President and CEO Maria Maccecchini, Ph.D.. The presentation will review the company’s recent progress, ongoing late‑stage clinical programs in Alzheimer’s and Parkinson’s disease, strategic direction, and upcoming early‑2026 milestones, followed by a live Q&A.
The webinar is open to shareholders, patients, investigators, and other interested parties; participants are encouraged to register via the company registration link and may submit questions in advance to ir@annovisbio.com.
Positive
- None.
Negative
- None.
News Market Reaction – ANVS
In the Dec 16 session, ANVS gained 3.97%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 03 | Conference presentation | Positive | +5.4% | Phase 3 Parkinson’s biomarker data presented at Parkinson Study Group meeting. |
| Nov 24 | Conference presentations | Positive | +7.9% | Two CTAD 2025 presentations on buntanetap cognition and Phase 3 AD design. |
| Nov 18 | Regulatory meeting | Positive | +11.2% | FDA Type C meeting scheduled for PDD and reaffirmed alignment on Phase 3 AD. |
| Nov 17 | Biomarker update | Positive | +29.5% | Phase 3 data showing halted cognitive decline and tau biomarker reductions. |
| Nov 12 | Earnings and update | Positive | +15.2% | Q3 2025 financials plus Phase 3 AD progress and new buntanetap PK data. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent company-specific news, especially clinical and regulatory milestones, has often been followed by positive price reactions.
Over the last months, Annovis has highlighted clinical and regulatory momentum around buntanetap in Parkinson’s and Alzheimer’s disease. On Nov 12, 2025, it reported Q3 results with $15.3M in cash and operational runway to Q3 2026, alongside activation of 84 Phase 3 AD sites. Subsequent updates on biomarker data, FDA meeting plans, and major conference presentations (CTAD and Parkinson Study Group) each coincided with positive one-day price moves, showing the market’s sensitivity to clinical progress. Today’s webinar announcement fits into this ongoing communication cadence.
Key Terms
Alzheimer's disease medical
Parkinson's disease medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
MALVERN, Pa., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it will host a corporate update webinar followed by a live Q&A session.
The webinar will feature Maria Maccecchini, Ph.D., President and CEO, who will provide an overview of the Company’s recent progress, ongoing clinical programs, and strategic directions.
Webinar details
- Date: Wednesday, January 28, 2026
- Time: 4:30 p.m. ET
- Presenter: Maria Maccecchini, Ph.D., President and CEO
- Registration link
“We look forward to beginning the year by sharing a comprehensive update on Annovis with everyone who has been following our journey,” said Maria Maccecchini, Ph.D., President and CEO. “The Company has witnessed strong momentum driven by clinical progress and corporate achievements, with additional milestones expected in early 2026. During this webinar, we will share where we are today, outline our path forward, and engage in direct dialogue with the community.”
The webinar is open to shareholders, patients, investigators, and other interested parties. Participants are encouraged to submit questions in advance by emailing ir@annovisbio.com.
About Annovis
Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). The Company is committed to developing innovative therapies that improve patient outcomes and quality of life. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.
Investor Alerts
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts.
Forward-Looking Statements
This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.
Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com
Investor Contact:
Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
ir@annovisbio.com
